STOCK TITAN
  1. Home
  2. Sec-filings
  3. ENTX
  4. [Form 4] Entera Bio Ltd. Insider Trading Activity

Entera Bio Ltd. (NASDAQ: ENTX) director reports 2026 share and option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Entera Bio Ltd. filed insider transaction details showing equity-based compensation for a company director. On 01/01/2026, the director received 38,294 ordinary shares with par value NIS 0.0000769 per share, reported at a price of $0, in lieu of cash fees for services as a director for the 2025 fiscal year. Following this transaction, the director reported beneficial ownership of 338,454 ordinary shares held directly.

The filing also reports a grant of a stock option on 01/01/2026 to purchase 33,505 ordinary shares at an exercise price of $1.94 per share. These options represent the Board’s annual grant to directors and vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026.

Positive

  • None.

Negative

  • None.
Insider LIEBERMAN GERALD M
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 33,505 $0.00 --
Grant/Award Ordinary Shares, par value NIS 0.0000769 per share 38,294 $0.00 --
holding Ordinary Shares, par value NIS 0.0000769 per share -- -- --
holding Ordinary Shares, par value NIS 0.0000769 per share -- -- --
holding Ordinary Shares, par value NIS 0.0000769 per share -- -- --
holding Ordinary Shares, par value NIS 0.0000769 per share -- -- --
Holdings After Transaction: Stock Option (right to buy) — 33,505 shares (Direct); Ordinary Shares, par value NIS 0.0000769 per share — 338,454 shares (Direct); Ordinary Shares, par value NIS 0.0000769 per share — 6,200 shares (Indirect, By Trust)
Footnotes (1)
  1. The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the 2025 fiscal year. These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LIEBERMAN GERALD M
(Last) (First) (Middle)
KIRYAT HADASSAH
MINRAV BUILDING, 5TH FLOOR
(Street)
JERUSALEM L3 9112002
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Entera Bio Ltd. [ ENTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/01/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares, par value NIS 0.0000769 per share 01/01/2026 A(1) 38,294 A $0 338,454 D
Ordinary Shares, par value NIS 0.0000769 per share 6,200 I By Trust(2)
Ordinary Shares, par value NIS 0.0000769 per share 6,200 I By Trust(2)
Ordinary Shares, par value NIS 0.0000769 per share 6,200 I By Trust(2)
Ordinary Shares, par value NIS 0.0000769 per share 6,200 I By Trust(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $1.94 01/01/2026 A 33,505 (3) 01/01/2036 Ordinary Shares, par value NIS 0.0000769 per share 33,505 $0 33,505 D
Explanation of Responses:
1. The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the 2025 fiscal year.
2. These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
3. These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026.
/s/ Dana Yaacov-Garbeli, Attorney-in-Fact 01/02/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Entera Bio Ltd. (ENTX) report in this Form 4?

The Form 4 reports that a director of Entera Bio Ltd. received 38,294 ordinary shares on 01/01/2026 as equity compensation, rather than cash fees, for serving as a director for the 2025 fiscal year.

How many Entera Bio (ENTX) shares does the reporting person own after the transaction?

After the reported transaction, the director beneficially owns 338,454 ordinary shares directly, as disclosed in the Form 4.

What stock options were granted to the Entera Bio (ENTX) director?

The director received a stock option on 01/01/2026 to purchase 33,505 ordinary shares at an exercise price of $1.94 per share. These options are described as the Board’s annual option grant to directors.

When do the Entera Bio (ENTX) director stock options vest and expire?

The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026, and have an expiration date of 01/01/2036.

Are any of the Entera Bio (ENTX) shares held indirectly by the reporting person?

The Form 4 identifies 6,200 ordinary shares held indirectly through a trust for which the reporting person’s grandchild is the beneficiary and the reporting person’s spouse is the trustee. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.

What is the relationship of the reporting person to Entera Bio Ltd. (ENTX)?

The reporting person is identified as a director of Entera Bio Ltd. and filed the Form 4 as a single reporting person.